1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Non-Small Cell Lung Cancer Partnering 2010-2015

Non-Small Cell Lung Cancer Partnering 2010-2015

  • March 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

The Non-Small Cell Lung Cancer Partnering 2010-2015 report provides understanding and access to the non-small cell lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in non-small cell lung cancer partnering deals
Top non-small cell lung cancer deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Non-Small Cell Lung Cancer Partnering 2010-2015 provides understanding and access to the non-small cell lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of non-small cell lung cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors non-small cell lung cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 60 links to online copies of actual non-small cell lung cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of non-small cell lung cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of non-small cell lung cancer technologies and products.

Report scope

Non-Small Cell Lung Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to non-small cell lung cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in non-small cell lung cancer dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 60 non-small cell lung cancer deals and contract documents where available
The leading non-small cell lung cancer deals by value since 2010

In Non-Small Cell Lung Cancer Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Non-Small Cell Lung Cancer Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in non-small cell lung cancer partnering

2.1. Introduction
2.2. Non-small cell lung cancer partnering over the years
2.3. Non-small cell lung cancer partnering by deal type
2.4. Non-small cell lung cancer partnering industry sector
2.5. Non-small cell lung cancer partnering by stage of development
2.6. Non-small cell lung cancer partnering by technology type

Chapter 3 - Average deal terms for non-small cell lung cancer

3.1 Introduction
3.2 Average deal terms for non-small cell lung cancer
3.3 Non-small cell lung cancer headline values with median calculation
3.4 Non-small cell lung cancer upfront values with median calculation
3.5 Non-small cell lung cancer milestone values with median calculation
3.6 Non-small cell lung cancer royalty rates with median calculation

Chapter 4 - Active non-small cell lung cancer dealmakers

4.1. Introduction
4.2 Most active non-small cell lung cancer dealmakers
4.3. Top non-small cell lung cancer deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Non-small cell lung cancer dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Non-small cell lung cancer partnering since 2010
Figure 2: Non-small cell lung cancer dealmaking activity- 2010 to 2015
Figure 3: Non-small cell lung cancer partnering by deal type since 2010
Figure 4: Non-small cell lung cancer partnering by industry sector since 2010
Figure 5: Non-small cell lung cancer partnering by stage of development since 2010
Figure 6: Non-small cell lung cancer partnering by technology type since 2010
Figure 7: Non-small cell lung cancer deals with a headline value
Figure 8: Non-small cell lung cancer deals with upfront payment values
Figure 9: Non-small cell lung cancer deals with milestone payments
Figure 10: Non-small cell lung cancer deals with royalty rates, %
Figure 11: Top non-small cell lung cancer deals by value since 2010
Figure 12: Big pharma - top 50 - non-small cell lung cancer deals 2010 to 2015
Figure 13: Big pharma non-small cell lung cancer deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - non-small cell lung cancer deals 2010 to 2015
Figure 15: Big biotech non-small cell lung cancer deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the UK

  • December 2016
    20 pages
  • Cancer  

  • United Kingdom  

    Europe  

View report >

Cancer Statistics in the US

  • December 2016
    112 pages
  • Cancer  

  • United States  

    North America  

View report >

Infectious Disease Statistics

  • December 2016
    6 pages
  • Infectious Dise...  

View report >

Related Market Segments :

Lung Cancer

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.